Status
Conditions
Treatments
About
Purpose of the Research: The primary aim of the proposed study is to conduct a randomized parallel-group 2-arm clinical trial investigating capnometry-guided respiratory intervention (CGRI) for pathological anxiety. CGRI aims to raise end-tidal CO2 levels thereby lowering hyperventilation-induced respiratory alkalosis and its associated fear-eliciting somatic reactions. Psycho-education about anxiety and its effects (PsyEd) will serve as a credible control comparator.
Full description
Low end-tidal CO2 (ETCO2), which is an accompanying feature of hyperventilation, has been associated with a variety of anxiety disorders, including panic disorder and social phobia. More recently, researchers have examined the efficacy of capnometry-guided respiratory intervention (CGRI) as a method for increasing ETCO2 and thereby reducing hyperventilation-induced anxiety/panic symptoms. Promising preliminary efficacy studies have shown that CGRI results in decreased panic symptom frequency and severity at a rate comparable to that of cognitive therapy. A recent uncontrolled proof-of-concept study showed that CGRI led to significant reductions in trauma symptoms in a sample of patients meeting DSM-5 criteria for PTSD. However, CGRI has not been adequately evaluated in the treatment of anxiety disorders other than panic disorder with or without agoraphobia.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Clinically elevated anxiety as indicated by an eight or higher on the Overall Anxiety Severity and Impairment Scale (OASIS).
Meets DSM-5 criteria for one or more of the following anxiety or trauma-related disorders as their "primary" mental disorder:
No current use of psychotropic medications or stable on current medications for at least 6 weeks
Age 18+.
Able to arrange transportation to our laboratory for study appointments.
Fluent in English.
Exclusion criteria
No history of medical conditions that would contraindicate participation in fear-provocation or respiratory challenges, including:
Not currently receiving other psychological treatment for anxiety.
No history of a suicide attempt within the past 6 months.
No history of psychosis within the past 6 months.
No history of moderate to severe alcohol or substance use disorder (with the exception of nicotine) within the past 3 months.
Does not endorse COVID-19 symptoms during the screening phase.
Primary purpose
Allocation
Interventional model
Masking
180 participants in 2 patient groups
Loading...
Central trial contact
Shristi Saraff; Michael J Telch, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal